ConductScience.org, home

Paper41345954

A novel immunocytokine promotes T cell- and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma.

Zhang X and 13 others. J Transl Med, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. A novel immunocytokine promotes T cell- and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma. Papers, record 41345954. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41345954

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A novel immunocytokine promotes T cell- and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma.
PubMed
Journal
J Transl Med
PubMed
Year
2025
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-07-24
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang XXiaoke
2Yang NNian
3Tang XXin
4Liu NNanxi
5Lu QQizhong
6Zhang ZZongliang
7Xu LLong
8Jiang LLu
9Ge HHonglin
10Lu HHuaqing
11Chen YYongdong
12Bao MMingbin
13Tong AAiping
14Zhou LLiangxuehttps://orcid.org/0000-0001-9991-6358

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
GlioblastomaMajor topic
T-LymphocytesMajor topic
CytokinesMajor topic
Brain NeoplasmsMajor topic
Killer Cells, NaturalMajor topic
Humans
Animals
Cell Line, Tumor
Interleukin-15
Tumor Microenvironment
Recombinant Fusion Proteins
Cytotoxicity, Immunologic

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82473334National Natural Science Foundation of ChinaPubMed
32471551National Natural Science Foundation of ChinaPubMed
2022CJE09013Major Scientific and Technological Achievements Transformation Project of Ningxia Hui Autonomous RegionPubMed
24CXTD15Project Fund of Sichuan Provincial HealthommissionPubMed
2023ZYDF097Mianyang Science and Technology BureauPubMed
NHC Key Laboratory of Nuclear Technology Medical Transformation(MIANYANG CENTRAL HOSPITAL)NHC Key Laboratory of Nuclear Technology Medical Transformation(MIANYANG CENTRAL HOSPITAL)PubMed

Source PubMed

Download CSV of grants

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135876221Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.ACS Nano2022https://conductscience.org/library/papers/35876221PubMed
232296583Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis.Cancer Biol Med2020https://conductscience.org/library/papers/32296583PubMed
337097811Engineering MMP-2 Activated Nanoparticles Carrying B7-H3 Bispecific Antibodies for Ferroptosis-Enhanced Glioblastoma Immunotherapy.ACS Nano2023https://conductscience.org/library/papers/37097811PubMed
428003994Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Front Oncol2016https://conductscience.org/library/papers/28003994PubMed
538167707IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.Nat Commun2024https://conductscience.org/library/papers/38167707PubMed
636371226Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies.J Hematol Oncol2022https://conductscience.org/library/papers/36371226PubMed
737409128IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation.Front Immunol2023https://conductscience.org/library/papers/37409128PubMed
828888485Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent.Cytokine Growth Factor Rev2017https://conductscience.org/library/papers/28888485PubMed
936056553CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.Mol Ther2023https://conductscience.org/library/papers/36056553PubMed
1038132354Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy.Biology (Basel)2023https://conductscience.org/library/papers/38132354PubMed
1127302161Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation.Cancer Res2016https://conductscience.org/library/papers/27302161PubMed
1224048123Innate and adaptive immune cells in the tumor microenvironment.Nat Immunol2013https://conductscience.org/library/papers/24048123PubMed
1333763293A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy.Oncoimmunology2021https://conductscience.org/library/papers/33763293PubMed
1438455459IL-15 in T-Cell Responses and Immunopathogenesis.Immune Netw2024https://conductscience.org/library/papers/38455459PubMed
1526206773The CD40/CD40L axis in glioma progression and therapy.Neuro Oncol2015https://conductscience.org/library/papers/26206773PubMed
1637564196B7-H3 in Brain Malignancies: Immunology and Immunotherapy.Int J Biol Sci2023https://conductscience.org/library/papers/37564196PubMed
1740794737A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors.Cancer Res Commun2025https://conductscience.org/library/papers/40794737PubMed
1835570396Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.Mol Ther2022https://conductscience.org/library/papers/35570396PubMed
1931332324CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.Nat Biotechnol2019https://conductscience.org/library/papers/31332324PubMed
2033589826Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity.Nat Protoc2021https://conductscience.org/library/papers/33589826PubMed

See all 51 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42891082Immunocytokines in cancer: a safety perspective.Front Immunol2026https://conductscience.org/library/papers/42891082PubMed
42545507Improving T-cell engager efficacy in glioblastoma with multi-antigen targeting and novel delivery approaches.Acta Neuropathol2026https://conductscience.org/library/papers/42545507PubMed
42396877Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment.Immunol Cell Biol2026https://conductscience.org/library/papers/42396877PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41345954

GET https://conductscience.org/api/papers/v1/41345954/references?page=2